The DOI matches its Crossref record; 485 of the 485 references it cites were found in a registry or an index.
Classification of current anticancer immunotherapies
Open accessAbstract
// Lorenzo Galluzzi 1,2,3,4,* , Erika Vacchelli 1,2,3 , José-Manuel Bravo-San Pedro 1,2,3 , Aitziber Buqué 1,2,3 , Laura Senovilla 1,2,3 , Elisa Elena Baracco 1,2,3,5 , Norma Bloy 1,2,3,5 , Francesca Castoldi 1,2,3,5,6 , Jean-Pierre Abastado 7 , Patrizia Agostinis 8 , Ron N. Apte 9 , Fernando Aranda 1,2,3,10 , Maha Ayyoub 11,12 , Philipp Beckhove 13 , Jean-Yves Blay 14,15 , Laura Bracci 16 , Anne Caignard 17,18 , Chiara Castelli 19 , Federica Cavallo 20 , Estaban Celis 21 , Vincenzo Cerundolo 22 , Aled Clayton 23,24 , Mario P. Colombo 19 , Lisa Coussens 25 , Madhav V. Dhodapkar 26 , Alexander M. Eggermont 3 , Douglas T. Fearon 27 , Wolf H. Fridman 2,4,28,29 , Jitka Fučíková 6,30 , Dmitry I. Gabrilovich 31 , Jérôme Galon 2,4,28,32 , Abhishek Garg 8 , François Ghiringhelli 33,34,35 , Giuseppe Giaccone 36,37 , Eli Gilboa 38 , Sacha Gnjatic 39 , Axel Hoos 40 , Anne Hosmalin 4,41,42,43 , Dirk Jäger 44 , Pawel Kalinski 45,46,47 , Klas Kärre 48 , Oliver Kepp 1,2,49 , Rolf Kiessling 50 , John M. Kirkwood 51 , Eva Klein 48 , Alexander Knuth 52 , Claire E. Lewis 53 , Roland Liblau 54,55,56 , Michael T. Lotze 45,46 , Enrico Lugli 57 , Jean-Pierre Mach 58 , Fabrizio Mattei 16 , Domenico Mavilio 57,59 , Ignacio Melero 60,61 , Cornelis J. Melief 62,63 , Elizabeth A. Mittendorf 64 , Lorenzo Moretta 65 , Adekunke Odunsi 66 , Hideho Okada 67 , Anna Karolina Palucka 68 , Marcus E. Peter 69 , Kenneth J. Pienta 70 , Angel Porgador 9 , George C. Prendergast 71,72,73 , Gabriel A. Rabinovich 74 , Nicholas P. Restifo 75 , Naiyer Rizvi 76 , Catherine Sautès-Fridman 2,4,28,29 , Hans Schreiber 77 , Barbara Seliger 78 , Hiroshi Shiku 79 , Bruno Silva-Santos 80 , Mark J. Smyth 81,82 , Daniel E. Speiser 83,84 , Radek Spisek 6,30 , Pramod K. Srivastava 85,86 , James E. Talmadge 87 , Eric Tartour 4,88,89,90 , Sjoerd H. Van Der Burg 91 , Benoît J. Van Den Eynde 92,93,94 , Richard Vile 95 , Hermann Wagner 96 , Jeffrey S. Weber 97 , Theresa L. Whiteside 46,98 , Jedd D. Wolchok 99,100 , Laurence Zitvogel 3,101,102 , Weiping Zou 103 and Guido Kroemer 1,2,4,49,104,* 1 Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France 2 INSERM, U1138, Paris, France 3 Gustave Roussy Cancer Campus, Villejuif, France 4 Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France 5 Faculté de Medicine, Université Paris Sud/Paris XI, Le Kremlin-Bicêtre, France 6 Sotio a.c., Prague, Czech Republic 7 Pole d’innovation thérapeutique en oncologie, Institut de Recherches Internationales Servier, Suresnes, France 8 Cell Death Research and Therapy (CDRT) Laboratory, Dept. of Cellular and Molecular Medicine, University of Leuven, Leuven, Belgium 9 The Shraga Segal Dept. of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel 10 Group of Immune receptors of the Innate and Adaptive System, Institut d’Investigacions Biomédiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain 11 INSERM, U1102, Saint Herblain, France 12 Institut de Cancérologie de l’Ouest, Saint Herblain, France 13 Translational Immunology Division, German Cancer Research Center, Heidelberg, Germany 14 Equipe 11, Centre Léon Bérard (CLR), Lyon, France 15 Centre de Recherche en Cancérologie de Lyon (CRCL), Lyon, France 16 Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy 17 INSERM, U1160, Paris, France 18 Groupe Hospitalier Saint Louis-Lariboisière - F. Vidal, Paris, France 19 Unit of Immunotherapy of Human Tumors, Dept. of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy 20 Molecular Biotechnology Center, Dept. of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy 21 Cancer Immunology, Inflammation and Tolerance Program, Georgia Regents University Cancer Center, Augusta, GA, USA 22 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK 23 Institute of Cancer & Genetics, School of Medicine, Cardiff University, Cardiff, UK 24 Velindre Cancer Centre, Cardiff, UK 25 Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA 26 Sect. of Hematology and Immunobiology, Yale Cancer Center, Yale University, New Haven, CT, USA 27 Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA 28 Université Pierre et Marie Curie/Paris VI, Paris, France 29 Equipe 13, Centre de Recherche des Cordeliers, Paris, France 30 Dept. of Immunology, 2nd Faculty of Medicine and University Hospital Motol, Charles University, Prague, Czech Republic 31 Dept. of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 32 Laboratory of Integrative Cancer Immunology, Centre de Recherche des Cordeliers, Paris, France 33 INSERM, UMR866, Dijon, France 34 Centre Georges François Leclerc, Dijon, France 35 Université de Bourgogne, Dijon, France 36 Center for Cance
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 401–485 of 485
Vacchelli, E., Galluzzi, L., Rousseau, V., Rigoni, A., Tesnière, A., Delahaye, N., Schlemmer, F., Menger, L., Sukkurwala, A. Q., Adjemian, S., et al. (2012) · OncoImmunology · doi:10.4161/onci.18684 · Cited by 53
Self-citationBadiee, A., Davies, N. M., McDonald, K. J., Radford, K. J., Michiue, H., Hart, D. N. J., & Kato, M. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.04.029 · Cited by 52
Gibney, G. T., Hamid, O., Gangadhar, T. C., Lutzky, J., Olszanski, A. J., Gajewski, T. F., Chmielowski, B., Boasberg, P. D., Zhao, Y., Newton, R. C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.3010 · Cited by 52
Self-citationMolecular mechanisms of the antitumor effects of anti-CD20 antibodies
Winiarska, M. (2010) · Frontiers in bioscience · doi:10.2741/3688 · Cited by 50
Lim, C. M., Stephenson, R. M., Salazar, A. Μ., & Ferris, R. L. (2013) · OncoImmunology · doi:10.4161/onci.24677 · Cited by 50
Immune effects of 5-fluorouracil
Ghiringhelli, F., Bruchard, M., & Apétoh, L. (2013) · OncoImmunology · doi:10.4161/onci.23139 · Cited by 49
Self-citationClinical Development of Oncolytic Viruses in China
Liang, M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958760 · Cited by 49
Monjazeb, A. M., Zamora, A. E., Grossenbacher, S. K., Mirsoian, A., Sckisel, G. D., & Murphy, W. J. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00197 · Cited by 48
Ray, S., Chhabra, A., Chakraborty, N. G., Hegde, U. P., Dorsky, D. I., Chodon, T., von Euw, E., Comin-Anduix, B., Koya, R. C., Ribas, A., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.04.013 · Cited by 48
Hoffman, E. S., Smith, R. E. T., & Renaud, R. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1880 · Cited by 48
Choi, I., Li, Y., Oh, E., Kim, J., & Yun, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067512 · Cited by 47
Activation of dendritic cells by tumor cell death
Cirone, M., Renzo, L. D., Lotti, L. V., et al. (2012) · OncoImmunology · doi:10.4161/onci.20428 · Cited by 47
Mansfield, A. S., Nevala, W. K., Lieser, E. A. T., Leontovich, A. A., & Markovic, S. N. (2013) · OncoImmunology · doi:10.4161/onci.24436 · Cited by 46
An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis
Lampe, J. W., Bossow, S., Weiland, T., Smirnow, I., Lehmann, R., Neubert, W. J., Bitzer, M., & Lauer, U. M. (2013) · Gene Therapy · doi:10.1038/gt.2013.28 · Cited by 46
Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
Cooper, Z. A., Frederick, D. T., Ahmed, Z., & Wargo, J. A. (2013) · OncoImmunology · doi:10.4161/onci.24320 · Cited by 45
Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines
García-Vallejo, J. J., Unger, W. W. J., Kalay, H., & van Kooyk, Y. (2013) · OncoImmunology · doi:10.4161/onci.23040 · Cited by 44
Fusions between dendritic cells and whole tumor cells as anticancer vaccines
Koido, S., Homma, S., Okamoto, M., Namiki, Y., Takakura, K., Uchiyama, K., Kajihara, M., Arihiro, S., Imazu, H., Arakawa, H., et al. (2013) · OncoImmunology · doi:10.4161/onci.24437 · Cited by 43
Genetically modulating T-cell function to target cancer
Merhavi-Shoham, E., Haga-Friedman, A., & Cohen, C. J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.006 · Cited by 43
Mittendorf, E. A., Gurney, J. M., Storrer, C. E., Shriver, C. D., Ponniah, S., & Peoples, G. E. (2006) · Surgery · doi:10.1016/j.surg.2005.06.059 · Cited by 42
Self-citationAntigen loss and tumor-mediated immunosuppression facilitate tumor recurrence
Olson, B. M., & McNeel, D. G. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.107 · Cited by 42
Robertson, M. J., Kline, J. P., Struemper, H., Koch, K. M., Bauman, J. W., Gardner, O., Murray, S. C., Germaschewski, F., Weisenbach, J., Jonak, Z., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31829d7e2e · Cited by 41
Impact of myeloid cells on the efficacy of anticancer chemotherapy
Senovilla, L., Aranda, F., Galluzzi, L., & Kroemer, G. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.05.009 · Cited by 40
Self-citationBeatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Newton, R. C., Schaub, R., Maleski, J. E., Leopold, L. H., & Gajewski, T. F. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3025 · Cited by 40
Santegoets, S. J. A. M., Turksma, A. W., Powell, D. J., Hooijberg, E., & de Gruijl, T. D. (2013) · OncoImmunology · doi:10.4161/onci.24522 · Cited by 39
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Galluzzi, L., Kroemer, G., & Eggermont, A. M. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967147 · Cited by 39
Self-citationRegulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody
Choi, B. D., Gedeon, P. C., Sanchez-Perez, L. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.26757 · Cited by 39
Camisaschi, C., Filipazzi, P., Tazzari, M., Casati, C., Beretta, V., Pilla, L., Patuzzo, R., Maurichi, A., Cova, A., Maio, M., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1397-7 · Cited by 38
Self-citationWei, H., Zhao, L., Hellström, I., Hellström, K. E., & Guo, Y. (2014) · OncoImmunology · doi:10.4161/onci.28248 · Cited by 37
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Peng, W., Lizee, G. A., & Hwu, P. (2013) · OncoImmunology · doi:10.4161/onci.22691 · Cited by 36
Antibody-dependent cell cytotoxicity in monoclonal antibody-mediated tumor immunotherapy
Hubert, P., & Amigorena, S. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17963 · Cited by 36
Besser, M. J., Shoham, T., Harari‐Steinberg, O., Zabari, N., Ortenberg, R., Yakirevitch, A., Nagler, A., Loewenthal, R., Schachter, J., & Markel, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057922 · Cited by 36
Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas
Shinoura, N., Yoshida, Y., Asai, A., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700160 · Cited by 36
Chawla, A., Philips, A. V., Alatrash, G., & Mittendorf, E. A. (2014) · OncoImmunology · doi:10.4161/onci.28325 · Cited by 35
Self-citationPotent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine
Hangalapura, B. N., Oosterhoff, D., de Groot, J., Boon, L., Tüting, T., van den Eertwegh, A. J. M., Gerritsen, W. R., van Beusechem, V. W., Pereboev, A. V., Curiel, D. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0804 · Cited by 35
RNA pulsed dendritic cells: An approach for cancer immunotherapy
Garg, N. K., Dwivedi, P., Prabha, P. S., & Tyagi, R. K. (2013) · Vaccine · doi:10.1016/j.vaccine.2012.12.027 · Cited by 35
Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology
Dranoff, G. (2013) · Nature Medicine · doi:10.1038/nm.3335 · Cited by 34
The expanding family of dendritic cell subsets
Ueno, H., Palucka, A. K., & Banchereau, J. (2010) · Nature Biotechnology · doi:10.1038/nbt0810-813 · Cited by 33
Self-citationTato, C. M., & Cua, D. J. (2008) · Cell · doi:10.1016/j.cell.2008.01.002 · Cited by 33
Current trends of anticancer immunochemotherapy
Vacchelli, E., Prada, N., Kepp, O., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25396 · Cited by 32
Self-citationSow, H. S., & Mattarollo, S. R. (2013) · OncoImmunology · doi:10.4161/onci.27058 · Cited by 32
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
Armeanu–Ebinger, S., Hoh, A., Wenz, J., & Fuchs, J. (2012) · OncoImmunology · doi:10.4161/onci.22620 · Cited by 32
CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
Waitz, R., Fassò, M., & Allison, J. P. (2012) · OncoImmunology · doi:10.4161/onci.19442 · Cited by 32
Hasumi, K., Aoki, Y., Wantanabe, R., & Mann, D. L. (2013) · OncoImmunology · doi:10.4161/onci.26381 · Cited by 32
Houot, R., Kohrt, H. E. K., & Levy, R. (2012) · OncoImmunology · doi:10.4161/onci.19974 · Cited by 31
Michielsen, A. J., Ryan, E. J., & O'Sullivan, J. N. (2012) · OncoImmunology · doi:10.4161/onci.21318 · Cited by 31
Pembrolizumab for treatment of refractory melanoma
Bagcchi, S. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70348-1 · Cited by 30
Re-orienting the immune system
Lipson, E. J. (2013) · OncoImmunology · doi:10.4161/onci.23661 · Cited by 30
Harfuddin, Z., Kwajah, S., Sim, A. C. N., MacAry, P. A., & Schwarz, H. (2013) · OncoImmunology · doi:10.4161/onci.26859 · Cited by 30
Assessing T-cell responses in anticancer immunotherapy
Escors, D., Liechtenstein, T., Pérez‐Janices, N., Schwarze, J. K., Dufait, I., Goyvaerts, C., Lanna, A., Vargas, F. A., Blanco‐Luquin, I., Kochan, G. T., et al. (2013) · OncoImmunology · doi:10.4161/onci.26148 · Cited by 29
Newton, R. C., Scherle, P., Bowman, K., Liu, X., Beatty, G. L., O'Dwyer, P. J., Gajewski, T. F., Bowman, J., Schaub, R., & Leopold, L. H. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2500 · Cited by 29
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation
Adler, A. J., & Vella, A. T. (2012) · OncoImmunology · doi:10.4161/onci.22837 · Cited by 28
Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia
Walter, R. B. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.896190 · Cited by 27
Lessons learned from a highly-active CD22-specific chimeric antigen receptor
Long, A. H., Haso, W. M., & Orentas, R. J. (2013) · OncoImmunology · doi:10.4161/onci.23621 · Cited by 27
Cytotoxic Dendritic Cells Generated from Cancer Patients
Lakomy, D., Janikashvili, N., Fraszczak, J., Trad, M., Audia, S., Samson, M., Ciudad, M., Vinit, J., Vergely, C., Caillot, D., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1004146 · Cited by 27
Yamada, Y., Aoyama, A., Tocco, G., Boskovic, S., Nadazdin, O., Alessandrini, A., Madsen, J. C., Cosimi, A. B., Bénichou, G., & Kawai, T. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200656 · Cited by 26
Uncovering the mechanisms that regulate tumor-induced T-cell anergy
Abe, B. T., & Macián, F. (2013) · OncoImmunology · doi:10.4161/onci.22679 · Cited by 24
Chacon, J. A., Pilon‐Thomas, S., Sarnaik, A. A., et al. (2013) · OncoImmunology · doi:10.4161/onci.25581 · Cited by 24
Foy, K. C., Miller, M. J., Moldovan, N. I., Božanović, T., Carson, W. E., & Kaumaya, P. T. P. (2012) · OncoImmunology · doi:10.4161/onci.21057 · Cited by 22
Omori, R., Eguchi, J., Hiroishi, K., Ishii, S., Hiraide, A., Sakaki, M., Doi, H., Kajiwara, A., Ito, T., Kogo, M., et al. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.42 · Cited by 22
Won’t you come on in? How to favor lymphocyte infiltration in tumors
Bellone, M., Calcinotto, A., & Corti, A. (2012) · OncoImmunology · doi:10.4161/onci.20213 · Cited by 22
Schnurr, M., & Duewell, P. (2013) · Oncoimmunology · doi:10.4161/onci.24170 · Cited by 22
Immunological effects of chemotherapy in spontaneous breast cancers
Kroemer, G., Galluzzi, L., & Zitvogel, L. (2013) · OncoImmunology · doi:10.4161/onci.27158 · Cited by 22
Self-citationA phase I study of indoximod in combination with docetaxel in metastatic solid tumors.
Jackson, E., Dees, E. C., Kauh, J. S. W., Harvey, R. D., Neuger, A. M., Lush, R. M., Antonia, S. J., Minton, S. E., Ismail-Khan, R. R., Han, H. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3026 · Cited by 22
Choi, B. D., Pastan, I. H., Bigner, D. D., & Sampson, J. H. (2013) · OncoImmunology · doi:10.4161/onci.23639 · Cited by 20
Novel insights into the mechanism of action of lenalidomide
Semeraro, M., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.28386 · Cited by 19
Self-citationNK cells from pleural effusions are potent antitumor effector cells
Terme, M., Fridman, W. H., & Tartour, É. (2013) · European Journal of Immunology · doi:10.1002/eji.201243264 · Cited by 18
Self-citationMassari, I., Donnini, A., Argentati, K., Straino, S., Mangoni, A., Gaetano, C., Viticchi, C., Capogrossi, M. C., & Provinciali, M. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00011-6 · Cited by 18
Cell type specific gene delivery by lentiviral vectors
Zhou, Q., & Buchholz, C. J. (2013) · OncoImmunology · doi:10.4161/onci.22566 · Cited by 18
Mavilio, D., & Lugli, E. (2013) · OncoImmunology · doi:10.4161/onci.26535 · Cited by 18
Self-citationDendritic cell-based immunotherapy in ovarian cancer
Coosemans, A., Vergote, I. B., & Gool, S. W. V. (2013) · OncoImmunology · doi:10.4161/onci.27059 · Cited by 17
You, C., Shi, M., Liu, Y., Cao, M., Luo, R., & Hermonat, P. L. (2012) · OncoImmunology · doi:10.4161/onci.20504 · Cited by 17
A novel strategy for modulation of MDSC to enhance cancer immunotherapy
Ghansah, T. (2012) · OncoImmunology · doi:10.4161/onci.20201 · Cited by 16
Immune effectors required for the therapeutic activity of vorinostat
Kepp, O., Galluzzi, L., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.27157 · Cited by 15
Self-citationPredictive immunomonitoring — The COST ENTIRE initiative
Popadic, D. M., Anegón, I., Baeten, D., Eibel, H., Giese, T., Marits, P., Martínez-Cáceres, E. M., Mascart, F., Nestle, F. O., Pujol‐Borrell, R., et al. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.01.013 · Cited by 15
Self-citationAgur, Z., & Vuk‐Pavlović, S. (2012) · OncoImmunology · doi:10.4161/onci.20955 · Cited by 14
New immunotherapeutic paradigms for castration-resistant prostate cancer
Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26084 · Cited by 13
Self-citationImmunological checkpoint inhibitors enter adolescence
Nowak, A. K. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70401-7 · Cited by 13
A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer.
Soliman, H. H., Minton, S. E., Ismail-Khan, R. R., Han, H. S., Vahanian, N. N., Ramsey, W. J., Kennedy, E. P., Link, C. J., Sullivan, D. M., & Antonia, S. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.tps3124 · Cited by 12
Lerret, N. M., & Marzo, A. L. (2013) · OncoImmunology · doi:10.4161/onci.22731 · Cited by 11
Ipilimumab success in melanoma provides boost for cancer immunotherapy
(2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3245 · Cited by 9
Ricupito, A., Grioni, M., Calcinotto, A., & Bellone, M. (2013) · OncoImmunology · doi:10.4161/onci.25032 · Cited by 8
Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens
Aruga, A. (2013) · OncoImmunology · doi:10.4161/onci.24882 · Cited by 7
An allogeneic NK cell line engineered to express chimeric antigen receptors
Badoual, C., Bastier, P. ‐., Roussel, H., Mandavit, M., & Tartour, É. (2013) · OncoImmunology · doi:10.4161/onci.27156 · Cited by 6
Rejuvenated T cells attack old tumors
Galluzzi, L., & Lugli, E. (2013) · OncoImmunology · doi:10.4161/onci.24103 · Cited by 5
Self-citationA Phase 2 Study of Docetaxel in Combination with Indoximod for Metastatic Breast Cancer
Kennedy, E. P., Soliman, H. H., Ismail-Khan, R. R., Han, H. S., Rossi, G. R., Vahanian, N. N., Link, C., Sullivan, D. M., & Antonia, S. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu467.15 · Cited by 2
Cited by
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Self-citationGuidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Self-citationCurrent Challenges in Cancer Treatment
Zugazagoitia, J., Guedes, C., Ponce, S., Ferrer, I., Molina-Pinelo, S., & Paz-Ares, L. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.03.026 · Cited by 926
Immunity, inflammation, and cancer: an eternal fight between good and evil
Shalapour, S., & Karin, M. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80007 · Cited by 698
Metadata
- Authors
- Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., Apte, R. N., Aranda, F., Ayyoub, M., Beckhove, P., Blay, J.-Y., Bracci, L., Caignard, A., Castelli, C., Cavallo, F., Celis, E., Cerundolo, V., Clayton, A., Colombo, M. P., Coussens, L., Dhodapkar, M. V., Eggermont, A. M., Fearon, D. T., Fridman, W. H., Fučíková, J., Gabrilovich, D. I., Galon, J., Garg, A., Ghiringhelli, F., Giaccone, G., Gilboa, E., Gnjatic, S., Hoos, A., Hosmalin, A., Jäger, D., Kalinski, P., Kärre, K., Kepp, O., Kiessling, R., Kirkwood, J. M., Klein, E., Knuth, A., Lewis, C. E., Liblau, R., Lotze, M. T., Lugli, E., Mach, J.-P., Mattei, F., Mavilio, D., Melero, I., Melief, C. J., Mittendorf, E. A., Moretta, L., Odunsi, A., Okada, H., Palucka, A. K., Peter, M. E., Pienta, K. J., Porgador, A., Prendergast, G. C., Rabinovich, G. A., Restifo, N. P., Rizvi, N., Sautès-Fridman, C., Schreiber, H., Seliger, B., Shiku, H., Silva-Santos, B., Smyth, M. J., Speiser, D. E., Spisek, R., Srivastava, P. K., Talmadge, J. E., Tartour, E., Van Der Burg, S. H., Van Den Eynde, B. J., Vile, R., Wagner, H., Weber, J. S., Whiteside, T. L., Wolchok, J. D., Zitvogel, L., Zou, W., & Kroemer, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-12-18
- Volume
- 5
- Issue
- 24
- Pages
- 12472-12508
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2134012905
- Cited by
- 468
- References
- 485
- FWCI
- 21.26
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.